Former President Joe Biden’s drug czar says the process to reschedule marijuana as initiated under the last administration may have been compromised by officials with the Drug Enforcement Administration (DEA), which was supposed to be defending the proposed policy change.
At the same time, a pro-legalization former OP congressman allied with President Donald Trump is raising questions about the sincerity of the current president’s endorsement of rescheduling on the campaign trail.
About four months into Trump’s second term, there has still been no movement on the pending plan to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), leaving advocates and stakeholders frustrated both by the current inaction but also the Biden administration’s failure to get the job done before the transition.
According to former White House Office of National Drug Control Policy (ONDCP) Director Rahul Gupta, that may have been due to deliberate resistance from within DEA—a suspicion shared widely among supporters of the reform, including those involved in an administrative hearing that’s been stalled for months, with no clear indication it will proceed any time soon.
“We got stuck moving at the slow speed of government, which was also marred, potentially, by some opposing it from within,” Gupta told The New York Times as part of a broader story examining the rescheduling effort.
The article also features interviews with a former senior DEA agent and former Rep. Matt Gaetz (R-FL), who notably suggested that Trump’s endorsement of a Schedule III reclassification on the campaign trail was essentially an attempt to shore up support among young voters rather than a sincere reflection of his personal views about cannabis.
As far as speculation about DEA’s role in the protracted process goes, there are several factors that have led many to conclude the agency’s leadership internally opposed the proposal, including the fact that there was a break in precedent when then-Attorney General Merrick Garland signed off on it after the U.S. Department of Health and Human Services (HHS) made the recommendation. Historically, the DEA administrator approves drug scheduling proposals.
Hellbound and Down 